Synthego, which is developing a ML-based approach to engineering genomes, raises $100M Series D led by Wellington Management, bringing total raised to $250M+
Kyle Wiggers / VentureBeat :
Context & Ripple Effects
Synthego's $100M Series D, led by Wellington Management and lifting its total raised past $250M, extends a funding arc that has already backed machine learning at adjacent layers of the biology stack. Synthace's Antha OS raised to automate biological lab workflows, and DNAnexus pulled in a $100M round for cloud-based genomics analytics just months before this deal — together covering the automation and data layers that ML-driven genome engineering sits on top of.
First-order effects
- Wellington Management's lead puts Synthego at a funding scale comparable to the largest AI-for-biology rounds in the coverage, such as Genesis Therapeutics' $200M Series B toward $280M total — capital it can deploy into scaling its ML-based genome engineering approach.
Second-order effects
- Upstream toolmakers benefit directly: an ML genome-engineering push depends on automated experiment execution and large-scale genomic data handling, strengthening demand for lab automation platforms like Synthace's Antha OS and cloud genomics infrastructure like DNAnexus.
Third-order effects
- If the pattern holds — capped most recently by [[a:843551|EvolutionaryScale's $40M+ seed for biology-focused LLMs built by ex-Meta protein-folding researchers]] — funding consolidates around vertically integrated platforms that pair foundation-style biological models with engineering capacity, rather than single-tool vendors.
The trend: Capital is stacking across every layer of ML-driven biology — lab automation, genomic data infrastructure, drug discovery, protein modeling, and now genome engineering — pushing the field from point tools toward integrated engineering platforms.